Strong Growth Ahead: Chronic Plaque Psoriasis Market Size To Grow At Arecord 7.1% Cagr By 2029

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

How Big Is the Chronic Plaque Psoriasis Market Size Expected to Be by 2034?
The market size of chronic plaque psoriasis has seen significant growth in the past few years. The market value will escalate from $20.79 billion in 2024 to $22.32 billion in 2025, growing at a compound annual growth rate (CAGR) of 7.3%. This growth during the historical period can be ascribed to the increasing number of psoriasis cases, a higher incidence of co-morbid conditions, advantageous reimbursement policies, a surge in alcohol and smoking consumption, and the emergence of telemedicine.

Predictions indicate that the market size for chronic plaque psoriasis will undergo significant growth in the coming years, climbing to $29.33 billion by 2029 with a compound annual growth rate (CAGR) of 7.1%. This growth during the projection period is likely due to rising and falling incidences of cpp worldwide, a surge in autoimmune diseases, expansion in healthcare budgets, an aging demographic, and increasing demand for effective treatments. Key trends expected during the forecast period include advancements in biologic treatments, the introduction of oral small molecule inhibitors, the incorporation of digital health, personalized medicine, and the arrival of biosimilars.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20726

What Are the Emerging Segments Within the Chronic Plaque Psoriasis Market?
The chronic plaque psoriasis market covered in this report is segmented -

1) By Drug Class: Biologics, Small Molecule Drugs
2) By Route Of Administration: Injectable, Oral, Topical
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:
1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors, Others
2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids, Others

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

What Long-Term Drivers Are Shaping Chronic Plaque Psoriasis Market Trends?
The rise in immune system disorders is set to fuel the expansion of the chronic plaque psoriasis market. An inefficient immune system indicates heightened vulnerability to infections, autoimmune diseases, and cancer. This surge in immune system dysfunction can be related to genetic factors, environmental triggers, poor nutrition, chronic stress, and a growing incidence of autoimmune diseases and infections, like HIV. Controlling immune system dysfunction necessitates treatment for chronic plaque psoriasis, as the immune system mistakenly triggers surplus skin cell production, leading to inflammation and plaque formation. For example, in December 2022, the US-based National Psoriasis Foundation, a nonprofit organization, disclosed that psoriasis affects over 8 million Americans. On a global scale, this condition affects 125 million people, representing 2 to 3% of the overall population. Thus, the escalating cases of immune system disorders are spurring the growth of the chronic plaque psoriasis market.

Who Are the Top Competitors in Key Chronic Plaque Psoriasis Market Segments?
Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim, Biogen Inc., UCB S.A., Dr. Reddy's Laboratories, Innovent Biologics Inc., Dong-A ST Co. Ltd., Alumis GmbH Co KG, Zai Lab Limited, GC Cell Corporation, Affibody AB, Nimbus Therapeutics, Bio-Thera Solutions, Can-Fite Biopharma, Celgene Corporation, Kadmon Pharmaceuticals, Aldeyra Therapeutics Inc., Arcutis Biotherapeutics

What Actigraphy Devices Market Trends Are Gaining Traction Across Different Segments?
In the chronic plaque psoriasis market, principal corporations are directing their efforts towards the creation of groundbreaking interventions such as IL-17A and IL-17F inhibitors, with the aim of advancing in chronic plaque psoriasis treatment. These inhibitors serve as targeted biological therapies that obstruct interleukin-17A and interleukin-17F, key pro-inflammatory cytokines, thus mitigating inflammation in autoimmune ailments like chronic plaque psoriasis. For instance, in October 2023, the U.S. FDA approved BIMZELX (bimekizumab-bkzx), a medication for psoriasis developed by UCB S.A., a biopharmaceutical firm based in Belgium. This drug is intended for adults with moderate to severe plaque psoriasis and who are suitable for systemic treatment or phototherapy. Bimekizumab stands out as the initial medication for psoriasis particularly aimed at curbing interleukin 17A (IL-17A) and interleukin 17F (IL-17F), both critical cytokines associated with inflammatory responses. This sanction was granted on the basis of results obtained from three phase 3 multi-site examinations - BE READY, BE VIVID, and BE SURE, where its efficacy and safety were evaluated among 1,480 patients dealing with moderate to severe plaque psoriasis.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

Which Regions Are Becoming Hubs for Chronic Plaque Psoriasis Market Innovation?
North America was the largest region in the chronic plaque psoriasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Chronic Plaque Psoriasis Market?
2. What is the CAGR expected in the Chronic Plaque Psoriasis Market?
3. What Are the Key Innovations Transforming the Chronic Plaque Psoriasis Industry?
4. Which Region Is Leading the Chronic Plaque Psoriasis Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.